Index

Page numbers in *italics* refer to Figures; those in **bold** to Tables.

acute tumor lysis syndrome, 109
actinomycin D, 95, 104
Adriamycin. **See** doxorubicin
adverse effects, 8–9, 90, 94, 101–112
age, chemotherapy and, 11
alanine aminotransferase, 48
Alkeran. **See** melphalan
alopecia, 9–10, 13, 22, 24, 90, 110
ALT. **See** alanine aminotransferase
Al. See alanine aminotransferase
anal sac carcinoma, 49, 98
anemia, 48
antibiotics, 9, 13, 47, 67, 108–109, 111–112
anticipatory grief, 114–115, 115
anxiety, owner and pet, 72, 75, 89, 114, 116
apoptosis, 16, 18, 24
appetite, 9, 41, 45, 54, 90, 106, 108, 110, 116, 123
AraC. **See** cytarabine
asparaginase, 83, 95–96, 103
auscultation, 43–44
behavior assessment, 72–73
Benadryl. **See** diphenhydramine
biochemistry profile, 48–49, 108
biological safety cabinet, 23, 25, 27, 59, 61, 62
biopsy, 5, 6
bladder tumors, 6, 49, 51, 98
blood tests. **See** laboratory tests
body map, 45, 55
body surface area, 29–30, 35, 45
brain tumors, 12–13, 49, 97
butterfly catheter. **See** catheters
calcium, 48
calipers, 45–46, 49
capsules, 10, 66, 79–80
carboplatin, 58, 67, 95
carcinogenesis, 17–18
carcinoma, 20–21, 49, 58, 95–97
cataracts, radiation-induced, 13
catheter, 30–33, 60, 65–66, 78, 80–85, 87–88, 104–105
CCNU. **See** lomustine
CDDP. **See** cisplatin
CeeNu. **See** lomustine
cell cycle, 94
cerebral vein, 78, 80
Cerenia. **See** maropitant
cisplatin, 48, 67, 82, 96
cemo-safety pen, 64
chemotherapy administration
intramuscular, 83–84, 95
intravenous, 80–88
oral, 10, 66, 79
setup for, 32, 80
subcutaneous, 83–86
children, 67, 115, 118–120, 127–128
chlorambucil, 96
client information sheet, 89–90, 102, 110–111
combination drug chemotherapy, 94
communication, 114
compassion fatigue, 130–131
Compazine. **See** prochlorperazine
complete blood count (CBC), 46–48, 108
complete response, 52
compounding, 25, 66
computed tomography (CT), 49–50
concentrated waste, 68
condolence card, 128–129
contaminated waste, 68
Cosmegen. **See** actinomycin D
crying, 116

CT. See computed tomography

cure, 52
cyclophosphamide, 11, 96–97, 99
cystitis, sterile hemorrhagic, 96–97
cystocentesis, 6
cytarabine, 83, 97
Cytoxan. See cyclophosphamide
cytosine arabinoside. See cytarabine
dactinomycin. See actinomycin D
denial, 116
Department of Public Health, 67
Department of Transportation (DOT), 61, 67
dexamethasone, 103–104, 104
dexrazoxane, 105
diabetes, 9, 24, 40–41, 54, 58, 90, 95, 106–107, 110–111
diet, 11, 41, 107, 111, 133
“difficult client,” 117
dimethyl sulfoxide (DMSO), 104
diphenhydramine, 103–104
disposal of chemotherapy drugs, 58, 60–61, 67–68, 79, 86, 88, 91
diuresis, 96
Drug Enforcement Agency (DEA), 67
electrolytes, 109
Elspar. See asparaginase
Elizabethan collar, 104
empathy, 121, 122, 124, 128, 130
end-of-life decisions, 125–127
endocrine disruptors, 67
environment, cancer development
and, 3–4
Environmental Protection Agency (EPA), 67, 69
epinephrine, 68, 103–104, 104
euthanasia, 123, 125–128
exposure, to chemotherapy, 9, 11, 24–25, 27, 33, 58, 60–61, 63–67, 81, 91,
extravasation, 46, 82, 103–105, 105
eye contact, 121
eyewash station, 33
facial expressions, 120–121
fever, 42–43, 108–109, 111–112
fine-needle aspiration, 5–6
Flagyl. See metronidazole
flow sheet, 88–89
flushing, of catheter, 66, 81, 85, 87
furosemide, 97

gastrointestinal (GI) toxicity, 94, 103, 106–107. See also diarrhea; nausea; vomiting
gloves, 10, 24, 26–27, 32–33, 59–62, 64, 66, 68, 79, 91
good day/bad day calendar, 125
gown, 26–27, 59–60, 62, 68, grade, 21
granulomatous meningoencephalitis, 97
grief, 114–129
children and, 118–120, 127–128
stages of, 117–118
hair loss. See alopecia
“Hallmarks of Cancer,” 18
handouts. See client information sheet
hazardous waste, 67–68
heart, damage to, 97, 105
heart rate, 42, 43–44, 108
hemangiosarcoma, 20, 49, 97
HEPA filter, 61–62, 64, 66
histiocytic sarcoma 97
histopathology, 7–8
history, 38–42, 53, 72, 103, 108
hospice, 126
hypercalcemia. See calcium
hypersensitivity reaction, 95, 97, 103–104, 104
imaging, 49–50
Imodium. See loperamide
initiation, in carcinogenesis, 18
invasion, 7–8, 17–19
isolator, 25, 27, 59, 61–63, 64, 66,
jugular vein, 46, 48, 74–75
keratoconjunctivitis sicca,
radiation-induced, 13
kidney values/function, 4, 11, 48–49, 95–97, 109
Kubler-Ross, Elizabeth, 117
L-asparaginase. See asparaginase
laboratory tests, 29, 45–49
Lasix. See furosemide
lateral recumbency, 76–77, 78
leukemia, 20, 95–97, 109
Leukeran. See chlorambucil
liver values, 49, 98
lomustine, 97–98
loperamide, 107
Luer-lock syringes, 26, 60, 64–65
lymphoma, 5, 11, 20, 52, 58, 95–99, 109, 114
magnetic resonance imaging, 49–50
mammary gland carcinoma, 49
margins, surgical, 8
maropitant, 107
mast cell tumor, 6, 7, 12, 20, 58, 97–98
Material Safety Data Sheet (MSDS), 25
measurement, of tumor size, 45
medical records, 28, 30, 40–41, 80
melanoma, 7, 12, 49, 95
melphalan, 98
metoclopramide, 107
metronidazole, 107
mesothelioma, 5
metastasis, 17–20
mitoxantrone, 98
MRI. See magnetic resonance imaging
muzzle, 75–77
myeloma, 98
nasal tumors, 12
National Institute for Occupational Safety and Health (NIOSH), 25, 61, 67, 87
nausea, 9, 41, 90, 106–107, 109–111
needle stick injuries, 88–88
neutropenia, 9, 29, 42, 47, 74, 94, 103, 107–109, 111–112
neutrophils, 47
nonverbal communication, 120–121
Novantrone. See mitoxantrone
Nuclear Regulatory Commission (NRC), 67
nursing, 91
Occupational Safety and Health Administration (OSHA), 61, 64, 67, 88
Oncovin. See vincristine
Onguard™, 25, 27, 32, 59–60, 64, 81, 84
open-ended questions, 39
oral chemotherapy drugs, 66, 79–80
oral tumors, 12
osteosarcoma, 7, 12, 20, 49, 95–97
over-the-needle catheter(s). See catheters
pain, 12–13, 17, 44, 104, 118, 123
pancreatitis, 107
Paraplacin. See carboplatin
partial response, 52
peri-anal tumors, 12
personal protective equipment (PPE), 26, 32–33, 59–60, 62, 79, 85
Phaseal™, 25, 27, 32, 59–60, 64–66, 81, 84
physical examination, 42
platelets, 47–48, 96, 98–99, 108
Platinol. See cisplatin
prednisone, 11
pregnancy, 61, 91
premalignancy, 17
preparation of chemotherapy, 63
prochlorperazine, 107
progression, in carcinogenesis, 18
progressive disease, 53
promotion, in carcinogenesis, 18
pulse, 43–44
pulse deficit, 44
quality of life, 10, 123–124
radiation therapy, 6, 12–13, 109
radiographs, 49–50
recapping of needles, 88
red blood cells, 48
reflection, as communication, 122
Reglan. See metoclopramide
Resource Conservation and Recovery Act (RCRA), 68
respirator, 26–27, 59,
respiratory rate/effort, 44
response assessment, 50–53
restraint for chemotherapy, 75–79
saphenous vein, 80
sarcoma, 20
sedation, 13, 50, 75, 88–90
self-disclosure, 122–123
sepsis, 107–109
side effect(s). See adverse effects
snake bite kit, 105
soft skills, 72–73, 79
soft-tissue sarcoma, 12, 20, 95–97, 99
spleen, tumors of, 6
spill kit, 27–28, 32, 60
stable disease, 52–53
stage, 21
Standard Operating Procedures (SOPs), 26, 59, 61
sternal recumbency, 76, 78
storage, of chemotherapy drugs, 60–61
suffering, 123–125
surface area. See body surface area
surgery, 6, 7
tachycardia, 44
temperature, 42–43, 74, 108, 111–112
therapeutic index, 94
thrombocytopenia. See platelets

touch, as communication, 121

TPR, 42–44, 74

transmissible venereal tumor, 99
tumors, benign versus malignant, 16
tumor suppressor genes, 17
tylosin, 107

ultrasound, 49–51
urinalysis, 48–49
urine specific gravity, 48–49
USP 797 protocol, 63

vaccine-associated sarcoma. See soft-tissue sarcoma

Velban. See vinblastine

vesicant drugs, 30–31, 74, 78, 81

Villalobos technique, 105

vinblastine, 58–59, 98, 104
vincristine, 11, 25, 58–59, 81, 90, 96, 99, 104

vomiting, 9, 41, 106–107, 109–111

waste disposal container, 27, 68–69

weight, 45

white blood cells, 46–47, 111–112
  lowering of, see neutropenia

Worden, William, 117

workspace, for chemotherapy administration, 32–33

X-rays. See radiographs

Zinecard. See dexrazoxane